Author:
Ollila Thomas A.,Olszewski Adam J.
Funder
American Cancer Society
National Institute of General Medical Sciences
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference128 articles.
1. Swerdlow SH, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. ed. World Health Organization classification of tumours. Lyon: International Agency for Research on Cancer; 2017.
2. Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014;89(3):310–4.
https://doi.org/10.1002/ajh.23638
.
3. El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D, et al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: a Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol. 2015;90(11):1041–6.
https://doi.org/10.1002/ajh.24169
.
4. Hui D, Proctor B, Donaldson J, Shenkier T, Hoskins P, Klasa R, et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma. 2010;51(9):1658–67.
https://doi.org/10.3109/10428194.2010.504872.
5. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117–26.
https://doi.org/10.1200/JCO.2005.09.131
.
Cited by
108 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献